ALDX stock news

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 15) AbbVie Inc (NYSE: ABBV ) Acer Therapeutics Inc (NASDAQ: ACER ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Alector Inc (NASDAQ: ALEC ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced pricing of its $6.5 million common stock offering at $1 per share) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genetic Technologies Limited (NASDAQ: GENE ) GENFIT S A/ADR (NASDAQ: GNFT ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Ironwood Pharmaceuticals, Inc. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 25) AbbVie Inc (NYSE: ABBV )(announced a deal to buy Allergan plc (NYSE: AGN ) for $63 billion) Acer Therapeutics Inc (NASDAQ: ACER )(The FDA issued complete response letter to its rare disease drug Edsivo) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aldeyra Therapeutics Inc (NASDAQ: ALDX )( reported negative results for the late-stage study that evaluated its reproxalap in anterior uveitis) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Axcella Health Inc (NASDAQ: AXLA ) Biopharmx Corp NYSE: (BPMX) (reported positive results for a Phase 2b clinical trial of BPX-04 in treating moderate-to-severe papulopustular rosacea) CELYAD SA/ADR (NASDAQ: CYAD ) Conatus Pharmaceuticals Inc (NASDAQ: CNAT )( announced decision to explore strategic alternatives following failed NASH drug trial) Enochian Biosciences Inc (NASDAQ: ENOB ) Evolent Health Inc (NYSE: EVH ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Myriad Genetics, Inc. Read more
Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX ), a thinly traded micro-cap biotech, plummeted Tuesday morning. What Happened Aldeyra, which focuses on therapies for immune-mediated diseases, reported its Phase 3 trial dubbed SOLACE that evaluated its reproxalap, code-named ADX-102 (a topical ophthalmic solution) in non-infectious anterior uveitis did not meet both the primary and secondary endpoints. Anterior uveitis is an inflammation of the middle layer … Full story available on Benzinga.com Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd … Read more
ALDX earnings call for the period ending . Read more
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q1 2019 Earnings Conference Call May 9, 2019 08:00 AM ET Company Participants Todd Brady - Chief Executive Officer Josh Read more

Aldeyra Therapeutics misses by $0.16

11:11am, Thursday, 09'th May 2019
Aldeyra Therapeutics (ALDX): Q1 GAAP EPS of -$0.58 misses by $0.16. Cash, cash equivalents, and marketable securities of $82.1M Press Release Read more
The following slide deck was published by Aldeyra Therapeutics, Inc. in conjunction with this event. Read more

Opening Bell, April 30, 2019

01:30pm, Tuesday, 30'th Apr 2019
Ringing today's opening bells are ViiV Healthcare Limited with Dr. John Pottage, senior VP and chief scientific and medical officer, at the NSYE and Aldeyra Therapeutics with President, Director and CEO Dr. Todd Brady at the Nasdaq. Read more

Today's Bell Ringer, April 30, 2019

01:15pm, Tuesday, 30'th Apr 2019
Today's bell ringers are ViiV Healthcare Limited with Dr. John Pottage, senior VP and chief scientific and medical officer, at the NSYE and Aldeyra Therapeutics with President, Director and CEO Dr. Todd Brady at the Nasdaq. Read more
Both Radius Health Inc. (NASDAQ:RDUS) and Aldeyra Therapeutics Inc. (NASDAQ:ALDX) are Biotechnology companies, competing one another. We will compare their analyst recommendations, profitability, risk Read more
Both Halozyme Therapeutics Inc. (NASDAQ:HALO) and Aldeyra Therapeutics Inc. (NASDAQ:ALDX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regard Read more
As Biotechnology businesses, Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), are affected by contrast. This especially applies to their profitability, institutio Read more
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and ContraFect Corporation (NASDAQ:CFRX) are two firms in the Biotechnology that compete against each other. Below is a Read more
The Earnings to Price yield of Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) is -0.157219. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one Read more

Proudly made at

ROCKIT